Annals of hematology · 2022
Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Klement Piroska, Fiedler Walter, Gabdoulline Razif, Dallmann Louisa-Kristin, Wienecke Clara Philine, Schiller Johannes, Kandziora Christian, Teich Katrin, Heida Bennett, Büttner Konstantin, Brandes Maximilian, Funke Carolin, Wichmann Martin, Othman Basem, Chromik Joerg, Amberg Stefanie, Kebenko Maxim, Schlipfenbacher Vera, Wilke Anne Christine, Modemann Franziska, Janning Melanie, Serve Hubert, Bokemeyer Carsten, Theile Susann, Deppermann Ute, Kranich Anne L, Ganser Arnold, Thol Felicitas, Heuser Michael
Аннотация
Relapse in patients with acute myeloid leukemia (AML) is common and is associated with a dismal prognosis. Treatment options are limited and the understanding of molecular response patterns is still challenging. We analyzed the clonal response patterns of 15 patients with relapsed/refractory AML treated with selinexor in a phase II trial (SAIL). DNA was analyzed at three time points and showed a decline of mutated alleles in FLT3, SF3B1, and TP53 under SAIL treatment. Overall survival (OS) was similar between patients with declining versus persisting clones. We show an interesting long-term course of a patient who relapsed after allogeneic stem cell transplantation (alloHCT) with SF3B1- and SRSF2-mutated AML and received selinexor as maintenance treatment for 4 years. Measurable residual disease (MRD) remained detectable for 2 weeks after donor lymphocyte infusion (DLI) in this patient and then remained negative under selinexor maintenance treatment. Selinexor was tolerated well and was stopped after 4 years of SAIL treatment. We present an exploratory study and identify subclonal patterns of patients treated with selinexor.